We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

35 hedge funds and large institutions have $1.11M invested in GT Biopharma in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.26% less ownership

Funds ownership: 0.56% → 0.3% (-0.26%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

63% less capital invested

Capital invested by funds: $3.05M → $1.11M (-$1.93M)

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$48.3K
2
Millennium Management
Millennium Management
New York
+$31.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$7.88K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.34K
5
MCG
McCollum Christoferson Group
New York
+$6.04K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.21M
2
BlackRock
BlackRock
New York
-$24.3K
3
Citadel Advisors
Citadel Advisors
Florida
-$20.4K
4
Jane Street
Jane Street
New York
-$10.4K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$9.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$343K -$9.7K -935 -2%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$262K +$48.3K +4,662 +31%
BlackRock
3
BlackRock
New York
$95.1K -$24.3K -2,342 -19%
Millennium Management
4
Millennium Management
New York
$73.3K +$31.8K +3,065 +64%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$69.7K – – –
BFS
6
Baskin Financial Services
Ontario, Canada
$47K – – –
Wells Fargo
7
Wells Fargo
California
$31.4K +$10 +1 +0%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$29.7K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$29K +$7.88K +760 +33%
State Street
10
State Street
Massachusetts
$25K -$653 -63 -2%
AWS
11
Atria Wealth Solutions
New York
$21.4K – – –
CLOS
12
Compagnie Lombard Odier SCmA
Switzerland
$15.6K – – –
Northern Trust
13
Northern Trust
Illinois
$10.1K – – –
Fidelity Investments
14
Fidelity Investments
Massachusetts
$7.19K -$9.62K -928 -55%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$6.63K +$7.34K +708 New
Jane Street
16
Jane Street
New York
$6.4K -$10.4K -1,004 -60%
SPC
17
Sigma Planning Corp
Michigan
$6.36K -$861 -83 -11%
TRCT
18
Tower Research Capital (TRC)
New York
$6.18K -$2.96K -286 -30%
MCG
19
McCollum Christoferson Group
New York
$5.46K +$6.04K +583 New
Goldman Sachs
20
Goldman Sachs
New York
$3.28K – – –
CSS
21
Cubist Systematic Strategies
Connecticut
$3.26K +$3.62K +349 New
MAWA
22
Moss Adams Wealth Advisors
Washington
$3.12K – – –
WG
23
Welch Group
Alabama
$3.12K – – –
Commonwealth Equity Services
24
Commonwealth Equity Services
Massachusetts
$3K – – –
Morgan Stanley
25
Morgan Stanley
New York
$2.52K – – –
1
2

GTBP Hedge Fund Activity: Q2 2023 in Review

35 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2023, worth a combined $1.11M — down 63% from $3.05M a quarter earlier.

Fund positioning in GTBP was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 8 trimmed.

The largest buyer was Bank of Montreal, adding an estimated $48.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.21M sold.

  • 35 institutional investors held GT Biopharma (GTBP) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $1.11M of GT Biopharma stock for Q2 2023, down 63% quarter-over-quarter.
  • 4 funds opened new GT Biopharma positions in Q2 2023 and 4 closed out, a net change of 0 holders.
  • The largest GT Biopharma buyer in Q2 2023 was Bank of Montreal, an estimated $48.3K added.
  • The largest GT Biopharma seller in Q2 2023 was Armistice Capital, an estimated $1.21M sold.

Based on aggregated 13F filings for Q2 2023.